These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34921596)

  • 41. Nusinersen Administration Via an Intrathecal Port in a 16-Year-Old Spinal Muscular Atrophy Patient with Profound Scoliosis.
    Flotats-Bastardas M; Linsler S; Zemlin M; Meyer S
    Pediatr Neurosurg; 2020; 55(1):54-57. PubMed ID: 31722365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
    Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
    Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?
    Yasar NE; Ozdemir G; Uzun Ata E; Ayvali MO; Ata N; Ulgu M; Dumlupınar E; Birinci S; Bingol I; Bekmez S
    J Child Orthop; 2024 Jun; 18(3):322-330. PubMed ID: 38831860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computed-tomography-guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations.
    Spiliopoulos S; Reppas L; Zompola C; Palaiodimou L; Papadopoulou M; Filippiadis D; Palialexis K; Ploussi A; Efstathopoulos E; Tsivgoulis G; Brountzos E
    Eur J Neurol; 2020 Jul; 27(7):1343-1349. PubMed ID: 32250518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: Transforaminal versus conventional approach.
    Bortolani S; Stura G; Ventilii G; Vercelli L; Rolle E; Ricci F; Bergui M; Mongini T
    Neuromuscul Disord; 2019 Oct; 29(10):742-746. PubMed ID: 31604650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination molecular therapies for type 1 spinal muscular atrophy.
    Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
    Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study.
    Shimizu-Motohashi Y; Chiba E; Mizuno K; Yajima H; Ishiyama A; Takeshita E; Sato N; Oba M; Sasaki M; Ito S; Komaki H
    Brain Dev; 2023 Mar; 45(3):161-170. PubMed ID: 36460551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spinal muscular atrophy with respiratory distress type 1 (SMARD1).
    Kaindl AM; Guenther UP; Rudnik-Schöneborn S; Varon R; Zerres K; Schuelke M; Hübner C; von Au K
    J Child Neurol; 2008 Feb; 23(2):199-204. PubMed ID: 18263757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.
    Matesanz SE; Curry C; Gross B; Rubin AI; Linn R; Yum SW; Kichula EA
    J Child Neurol; 2020 Oct; 35(11):717-723. PubMed ID: 32515646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
    Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
    Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
    [No Abstract]   [Full Text] [Related]  

  • 54. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis.
    Rosiak G; Lusakowska A; Milczarek K; Konecki D; Fraczek A; Rowinski O; Kostera-Pruszczyk A
    Neuroradiology; 2021 Apr; 63(4):539-545. PubMed ID: 33512541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database.
    Wataya T; Takasaki S; Hoshino M; Makioka H; Nakamura G; Matsuda N
    Int J Neurosci; 2023 Dec; 133(8):851-863. PubMed ID: 34809526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study.
    Stettner GM; Hasselmann O; Tscherter A; Galiart E; Jacquier D; Klein A
    BMC Neurol; 2023 Feb; 23(1):88. PubMed ID: 36855136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen.
    Ogawa K; Okanari K; Kobayashi O; Nakashima M; Ihara K
    Pediatr Int; 2019 Oct; 61(10):1051-1053. PubMed ID: 31612561
    [No Abstract]   [Full Text] [Related]  

  • 59. [Spinal muscular atrophy treated with nusinersen].
    Boesen MS; Albrechtsen S; Born AP
    Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
    Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
    Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.